I bough some ASM today. Seemed Phar. share doing good recently

The results the company posted last week showed that they had turned the corner and after years of increasing losses, they managed to post a smaller loss than the previous year for the first time, and the turnover was substatially increased from the previous years.

Take a look at the fundamentals (go to research) and compare the past years results against the one to June 2003

I saw an article from other magazone and strongly recommend to buy it and also they are doing other drug. Hopefullly it will the same as AZM.(a miracle rise) beside that I think it also have potentail to rise

this is the result of the intial evaluation of the R1549,it has some positive and some negative aspects to it, gauging by the slight drop in price it appears it has not been that weel recieved by the city, as people were expecting far more conclusive findings.. just my opinion



Antisoma PLC
06 November 2003

Broad potential for R1549 highlighted by favourable tolerability
profile in gastric cancer pilot study

London, UK, 6 November 2003: Antisoma plc (LSE:ASM), the biopharmaceutical
company specialising in the development of anti-cancer drugs, today announces
final results from its pilot phase II study of R1549 in gastric cancer. The
trial, which has been funded since November 2002 by Antisoma's co-development
partner, Roche, evaluated the drug in a small group of patients who had received surgery to treat advanced gastric cancer. Eight patients who received surgery plus R1549 were compared with seven patients who received surgery alone. Tolerability findings were comparable to those observed in patients receiving R1549 for ovarian cancer. As expected, based on the small size of the trial, no statistically significant differences were observed in survival time between the treated and untreated patients.

The importance of these results lies in the extension of favourable tolerability data to a broader patient population than ovarian cancer sufferers. The gastric study included patients with a different type of tumour, a different surgical history and for the first time men as well as women. This study makes possible the future evaluation of R1549 in gastric and other abdominal cancers in the event of positive results from the drug's pivotal phase III study in ovarian cancer. Antisoma and Roche expect to announce the principal results of the ovarian study during the first half of 2004. A previous phase II study in ovarian cancer showed a statistically significant increase in survival time, with enhanced five- and ten-year survival (details of the publications are provided in Notes to Editors).

An investigator in the study, Dr Bruce Sizer of Essex County Hospital,
Colchester, UK, said, 'This trial was a useful first step in evaluating R1549 in gastric cancer. Further trials will be needed to fully elucidate the value of the drug in this and other possible abdominal cancer indications.'

Glyn Edwards, CEO of Antisoma, said, 'This is an exciting time for Antisoma as
we await the results of our pivotal study of R1549 in ovarian cancer. By showing that R1549 can also be given safely to patients with gastric cancer, today's results provide a potential springboard for the extension of the development programme to a range of abdominal cancers.'



Enquiries:

Antisoma plc Tel: +44 (0)20 8799 8200
Glyn Edwards, Chief Executive Officer

Financial Dynamics Tel: +44 (0)20 7831 3113
Jonathan Birt


Except for the historical information presented, certain matters discussed in
this statement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the Company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.


Notes to editors

Gastric cancer

Approximately 875,000 new cases of gastric cancer are diagnosed worldwide each
year. Treatment options are limited and survival rates remain poor, as
approximately 80% of patients present with locally advanced or metastatic
disease. The World Health Organisation estimates that gastric cancer killed
almost 650,000 people worldwide in 2000.

References for ovarian cancer phase II study

Hird V. et al. Adjuvant therapy of ovarian cancer with radioactive
monoclonal antibody. Br J Cancer (1993) 68: 403-406.

Epenetos A.A. et al. Long term survival of patients with advanced
ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J
Gynecol Cancer (2000) 10 (suppl 1): 44-46.

Nicholson S. et al. Radioimmunotherapy after chemotherapy compared to
chemotherapy alone in the treatment of advanced ovarian cancer: A matched
analysis. Oncol Reports (1998) 5: 223-226.

kantona - actually it is very good news - have posted on the other thread what 1549 is really all about - if it can be even moderately successful against "the Whispering Disease" this share will fly. Main problem is no chance of takeover and even Roche can't bid until results of phase III are public. Not a short term punt.